Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 6/20 | 0.47 |
| ▸ | CCND1 | P24385 | 5/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 4/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407409 | 0.84 | MEN1 (0.50) | MEN1KMT2ACDK4CCND1DYRK1A | |
| SCHEMBL1407225 | 0.82 | MEN1 (0.48) | MEN1KMT2ACDK4CCND1DYRK1A | |
| SCHEMBL4028605 | 0.81 | PDE4A (0.49) | CHEK1FLT3PLK3CDK4CCND1 | |
| SCHEMBL1407062 | 0.81 | CHEK1 (0.43) | CHEK1FLT3PLK3MEN1KMT2A | |
| SCHEMBL1407747 | 0.81 | CYP1A2 (0.46) | CHEK1FLT3PLK3MEN1KMT2A | |
| SCHEMBL4025987 | 0.80 | CHEK1 (0.54) | CHEK1FLT3PLK3 | |
| SCHEMBL1407136 | 0.78 | MEN1 (0.44) | MEN1KMT2ACDK4CCND1DYRK1A | |
| SCHEMBL4033295 | 0.78 | PDE4A (0.46) | CHEK1FLT3PLK3MEN1KMT2A | |
| SCHEMBL2995599 | 0.76 | FBP1 (0.46) | MEN1KMT2ACDK4CCND1DYRK1A | |
| SCHEMBL31760855 | 0.74 | KDM4E (0.65) | CHEK1FLT3MEN1KMT2ACDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295429-A1 | 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases | Wyeth LLC (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2295429-A1 | 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases | Wyeth LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7592363-B2 | Indazoles | WYETH (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1773781-A2 | INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES | Wyeth (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006017384-A2 | INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES | WYETH (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030612-A1 | Indazoles useful in treating cardiovascular diseases | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030612-A1 | Indazoles useful in treating cardiovascular diseases | NR1H2, NR1H3, CYP46A1 | CHEK1 4389/4885FLT3 1871/4885PLK3 1427/4885 |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | CHEK1 4544/4885FLT3 1003/4885PLK3 1669/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | CHEK1 4650/4885FLT3 1901/4885PLK3 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.